KeyCorp Has Lowered Expectations for NeuroPace (NASDAQ:NPCE) Stock Price

Key Points

• KeyCorp cut its NeuroPace price target from $18 to $14 but maintained an “overweight” rating; the new target implies 16.47% upside from the stock’s current price.
• NeuroPace shares fell 4% and opened at $12.02. Analysts’ average rating is “Moderate Buy,” with a consensus price target of $16.43.
• Recent company updates cited in the article point to pressure on growth: quarterly revenue missed expectations, and NeuroPace lowered its 2026 revenue outlook to $91–$92 million, below analyst consensus.

NeuroPace (NASDAQ:NPCE - Get Free Report) had its target price decreased by stock analysts at KeyCorp from $18.00 to $14.00 in a research report issued on Friday, Benzinga reports. The firm currently has an "overweight" rating on the stock. KeyCorp's target price would indicate a potential upside of 16.47% from the stock's current price.

Other analysts also recently issued reports about the company. Guggenheim reiterated a "neutral" rating on shares of NeuroPace in a research report on Wednesday, July 29th. Mizuho assumed coverage on shares of NeuroPace in a research note on Thursday, July 23rd. They set an "outperform" rating and a $22.00 target price for the company. Cantor Fitzgerald restated an "overweight" rating on shares of NeuroPace in a report on Tuesday, September 15th. HC Wainwright reaffirmed a "buy" rating and issued a $20.00 price target on shares of NeuroPace in a research note on Wednesday, July 29th. Finally, JPMorgan Chase & Co. downgraded shares of NeuroPace from an "overweight" rating to a "neutral" rating and set a $9.00 price target on the stock. in a research note on Friday. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $16.43.

NeuroPace Stock Down 4.0%

Shares of NASDAQ NPCE opened at $12.02 on Friday. NeuroPace has a 1 year low of $11.90 and a 1 year high of $19.60. The firm has a 50-day simple moving average of $13.35 and a two-hundred day simple moving average of $14.79. The company has a market cap of $412.53 million, a P/E ratio of -21.09 and a beta of 1.98. The company has a debt-to-equity ratio of 4.97, a current ratio of 4.94 and a quick ratio of 3.91.

NeuroPace (NASDAQ:NPCE - Get Free Report) last released its earnings results on Tuesday, August 11th. The company reported ($0.18) EPS for the quarter, beating analysts' consensus estimates of ($0.22) by $0.04. NeuroPace had a negative return on equity of 105.64% and a negative net margin of 19.34%. The firm had revenue of $22.83 million for the quarter, compared to analysts' expectations of $22.61 million. Research analysts anticipate that NeuroPace will post -0.67 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Diversified Trust Co purchased a new position in NeuroPace during the third quarter valued at approximately $153,000. First Light Asset Management LLC raised its stake in NeuroPace by 16.3% in the second quarter. First Light Asset Management LLC now owns 2,861,167 shares of the company's stock worth $45,464,000 after buying an additional 401,201 shares in the last quarter. Bank of America Corp DE bought a new position in NeuroPace in the second quarter worth approximately $322,000. Man Group plc bought a new position in NeuroPace in the second quarter worth approximately $1,336,000. Finally, Hsbc Holdings PLC purchased a new stake in NeuroPace during the second quarter worth $420,000. Institutional investors own 78.83% of the company's stock.

Recent NeuroPace Headlines

Here are a few of the latest headlines about NPCE:

• Positive Sentiment: NeuroPace reported a quarterly loss of $0.03 per share, narrower than the $0.11 loss analysts expected and the $0.11 loss a year earlier. Zacks article
• Negative Sentiment: Revenue was $23.1 million, below analysts’ $27.12 million expectation. RNS System revenue was $22.9 million, up just 1.4% year over year, pointing to limited growth. NeuroPace earnings release
• Negative Sentiment: The company lowered its 2026 revenue outlook to $91 million–$92 million, well below the roughly $100.4 million analyst consensus. The guidance reduction, alongside the quarterly revenue miss, is the clearest near-term negative catalyst for NPCE shares. Coverage of NeuroPace’s reduced guidance

NeuroPace Company Profile

NeuroPace, Inc. is a medical technology company focused on treating people with drug-resistant epilepsy. Its primary product is the RNS System, an implanted responsive neurostimulation device designed to detect patterns of abnormal electrical activity in the brain and deliver stimulation in response. The RNS System includes a neurostimulator implanted in the skull and leads placed in or near seizure-onset areas of the brain. Clinicians use the system to review brain activity and adjust treatment, while patients can use accompanying tools to record information about their seizures and share it with their care team.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.